Contineum Therapeutics — Biomedical Watch V2

Traitements5programmes

Essais3liés

Publications1liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
PIPE-307This is a Phase 1, single-center, open-label, adaptive-design PET study to investigate the occupancy of brain muscarinic Type 1 receptors (M1AChR) by PIPE-307 in healthy volunteers.	SEP	Phase 1	À vérifier	Australia	Échec consolidé : au moins une étude associée à PIPE-307 est marquée en échec.
PIPE-791This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF). The purpose of this study is to find out how much of the study drug gets into the brain and lung, and what the side effects and blood levels of the study drug are in healthy volunteers and patients. Participants will: * Take a single dose of the study drug * Give many samples of blood and urine * Have multiple PET scans	SEP	Phase 1	À vérifier	United Kingdom	À vérifier
PIPE-307This is a Phase 1, single-center, open-label, adaptive-design PET study to investigate the occupancy of brain muscarinic Type 1 receptors (M1AChR) by PIPE-307 in healthy volunteers.	SEP	Phase 1	À vérifier	United Kingdom	Échec consolidé : au moins une étude associée à PIPE-307 est marquée en échec.
PIPE-307This is a Phase 1, single-center, open-label, adaptive-design PET study to investigate the occupancy of brain muscarinic Type 1 receptors (M1AChR) by PIPE-307 in healthy volunteers.	SEP	Phase 1	À vérifier	Australia	Échec consolidé : au moins une étude associée à PIPE-307 est marquée en échec.
PIPE-791This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF). The purpose of this study is to find out how much of the study drug gets into the brain and lung, and what the side effects and blood levels of the study drug are in healthy volunteers and patients. Participants will: * Take a single dose of the study drug * Give many samples of blood and urine * Have multiple PET scans	SEP	Phase 1	À vérifier	United Kingdom	À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
PIPE-791	SEP	Phase 1	NCT06683612	PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF	COMPLETED
PIPE-307	SEP	Phase 1	NCT04725175	Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers	COMPLETED
PIPE-307	SEP	Phase 1	NCT04941781	PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers	COMPLETED

Publications

1

Molécule	Indication / population	Titre	Journal	Date
PIPE-307		Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis.	Proceedings of the National Academy of Sciences of the United States of America